Drug Profile
Research programme: hypoglycaemia therapy - Roche
Alternative Names: MAR-531Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Marcadia Biotech
- Developer Roche
- Class Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypoglycaemia in USA (SC, Injection)
- 30 Dec 2010 Marcadia Biotech has been acquired and merged into Roche
- 28 Jun 2010 Marcadia Biotech and Eli Lilly and Company enter into an exclusive development and licensing agreement for the former's glucagon analogue programme. Under the agreement, Eli Lilly and Company is responsible for development outside the US, and for commercialisation worldwide